Tanezumab improves pain, function in OA, but safety events higher vs NSAID
Treatment with tanezumab appears to relieve pain and improve physical function in patients with hip or knee osteoarthritis (OA), but may lead to dose-dependent increase in joint safety events as compared with nonsteroidal anti-inflammatory drug (NSAID), according to the results of a phase III safety trial.
Tanezumab improves pain, function in OA, but safety events higher vs NSAID
18 Feb 2021